MCK · Q3 2026 Earnings

Bullish

McKesson Corporation

Reported February 4, 2026

30-second summary

McKesson delivered $106.2B Q3 revenue (+11% YoY) and $9.34 adjusted EPS, then raised FY26 adjusted EPS guidance by $0.40 at the midpoint to $38.80–$39.20 — the third in-year raise, bringing cumulative FY26 EPS growth guidance to +17–19% from the original +12–15%. Revenue growth guide lifted +100bps to +12–16% and operating profit growth +100bps to +13–17%, so this is an operational raise on top of the prior Norway and Investor Day raises. Oncology & Multispecialty accelerated to +37% YoY revenue ($13.0B) — above the +29–33% FY guide — and GLP-1 distribution revenue hit $14B (+26% YoY). North American Pharmaceutical Q3 came in at +9%, but 9M YTD is +13% (squarely mid-range of the +10–14% FY guide) and the Q3 print absorbed a ~3% prior-year held-for-sale comp headwind — a clean operational quarter end-to-end.

Headline numbers

EPS

Q3 FY2026

$9.34

Revenue

Q3 FY2026

$106.16B

+11.0% YoY

Gross margin

Q3 FY2026

3.5%

Free cash flow

Q3 FY2026

$1.10B

Operating margin

Q3 FY2026

1.5%

Key financials

Q3 FY2026

Metric	Q3 FY2026	YoY	Q2 FY2026	QoQ
Revenue	$106.16B	+11.0%	$103.15B	+2.9%
EPS	$9.34	—	$9.86	-5.3%
Gross margin	3.5%	—	3.4%	+4bps
Operating margin	1.5%	—	1.4%	+16bps
Free cash flow	$1.10B	—	$2.20B	-50.0%

Guidance

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

New guidance

Metric	Period	Guide	YoY
Interest expense	FY 2026	$215 to $235 million	—
Free cash flow	FY 2026	$4.4 to $4.8 billion	—
Income attributable to noncontrolling interests	FY 2026	$230 to $250 million	—
Effective tax rate	FY 2026	approximately 19%	—
Corporate expenses	FY 2026	$620 to $650 million	—
Share repurchase plan	FY 2026	approximately $2.5 billion	—
North American Pharmaceutical revenue growth	FY 2026	10% to 14%	—
North American Pharmaceutical operating profit growth	FY 2026	8% to 12%	—
Oncology & Multispecialty revenue growth	FY 2026	29% to 33%	—
Oncology & Multispecialty operating profit growth	FY 2026	51% to 55%	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Adjusted EPS	FY 2026	$38.35 to $38.85	$38.80 to $39.20	+$0.45 to +$0.35 (midpoint +$0.40)	Raised
Revenue growth	FY 2026	11% to 15%	12% to 16%	+1 percentage point at both ends	Raised
Operating profit growth	FY 2026	12% to 16%	13% to 17%	+1 percentage point at both ends	Raised
Adjusted EPS YoY growth	FY 2026	16% to 18%	17% to 19%	+1 percentage point at both ends	Raised

Segment KPIs

Q3 FY2026

Segment	Q3 FY2026	YoY
North American Pharmaceutical	$88.322B	+9.0%
Oncology & Multispecialty	$13.01B	+37.0%
Prescription Technology Solutions	$1.5B	+9.0%
Medical-Surgical Solutions	$2.991B	+1.0%

Other KPIs

Q3 FY2026

Segment	Q3 FY2026
North American Pharmaceutical Adjusted Operating Profit Margin	0.99%
Oncology & Multispecialty Adjusted Operating Profit Margin	2.81%
Prescription Technology Solutions Adjusted Operating Profit Margin	18.47%
Medical-Surgical Solutions Adjusted Operating Profit Margin	8.86%
Free Cash Flow Margin (9M)	0.71%
Operating Cash Flow (9M)	$2.734 billion
Share Repurchases (9M)	$2.1 billion
Dividend Payments (9M)	$0.28 billion

Management tone

Q4 FY25 (acquisition pivot) → Q1 FY26 (Norway-driven EPS raise + capital aggression) → Q2 FY26 (Med-Surg separation timeline + operational raise) → Q3 FY26 (third in-year raise, operational + ROIC framing).

Med-Surg separation has moved from announced timeline to demonstrated execution. Last quarter, management committed to an H2 CY2027 IPO target — concrete but distant. This quarter the milestone is operational: "On January 1st, we reached a major milestone in the separation journey with transition service agreements now in place across the enterprise. This is an important step as we prepare the medical surgical business to be an independent operation." TSAs in place is a real proof point that this isn't drifting — answering directly to our Q2 watch list concern about whether the H2 CY2027 timeline would hold without visible transaction prep.

The EPS raise narrative has fully transitioned from mechanical to operational. This quarter's $0.40 raise is unambiguous — revenue growth guide +100bps, operating profit growth guide +100bps, and EPS YoY growth +100bps simultaneously. Management's framing: "The consistency of this performance gives us the confidence to raise full-year EPS guidance to a range of $38.80 to $39.20, which reflects 17% to 19% year-over-year growth." The cumulative arc on the operating profit growth guide is the cleanest signal that the underlying earnings power has been re-rated.

Oncology has moved from designated growth pillar to high-momentum proof point. Q1 framed oncology as flywheel; Q2 made it a discrete reporting segment; this quarter management leans into organic disclosure: "Excluding the impact from acquisitions, organic operating profit increased 15%, highlighting the segment's strong underlying performance." Stripping out acquisition noise to demonstrate underlying momentum is unusual for McKesson and answers the Q2 watch question directly — organic operating profit growth held at +15%.

Capital efficiency has been re-anchored to a long-cycle ROIC narrative. Prior cycles emphasized opex/gross profit leverage and incremental margin gains. This quarter, management quantified the full cycle: "This consistent focus and execution has increased return on invested capital by more than 1,900 basis points since fiscal 2020 and now exceeding 30%." A 1,900bps ROIC improvement over five years is a structural framing — it positions the current portfolio (post-European exit, pending Med-Surg IPO) as having generated through-cycle capital efficiency that justifies the aggressive M&A pace. This is a posture shift from cyclical efficiency wins to structural capital-returns story.

AI/automation has shifted from infrastructure investment to demonstrated productivity yield. Q2 cited the 8-touches-to-2-touches automation framing; this quarter is more quantified — per Bank of America Q&A, "each full-time employee is successfully supporting 120 more patients than we achieved last year" and the DSCSA process is achieving 75% autonomous resolution. The narrative has crossed the threshold from "we're investing in automation" to "automation is delivering measurable productivity per employee" — important because it underwrites the segment-level margin expansion guidance.

Recurring themes management leaned on this quarter:

Oncology and multispecialty organic acceleration with 15% organic operating profit growthBiopharma services scaling with 50+ new programs and digitized patient enrollment capabilitiesNorth American pharma distribution resilience with double-digit specialty and GLP-1 growthAI and automation deployment driving measurable efficiency and customer experience gainsPortfolio optimization through completed European exit and imminent medical-surgical separationCapital deployment discipline supporting 18% 5-year EPS CAGR and 30%+ return on invested capital

Risks management surfaced:

GLP-1 growth may vary from quarter to quarterIllness season timing, severity, and duration could drive material variation in medical surgical resultsProduct delays and supply chain dynamics could affect biopharma services performanceFormulary requirements and utilization trends could impact access solution demandMedical-surgical separation subject to market conditions and regulatory approvals

Q&A highlights

Alan Letts · Bank of America

What specific technology and automation investments are being made to improve employee productivity during verification season? What is the longer-term margin opportunity in the segment?

Management highlighted investments in AI, large language models, and workflow automation tools that enable email automation and rapid agent processing. Cited DSCSA process achieving 75% autonomous resolution. Noted 130+ basis points year-over-year operating margin growth in the segment through automation and service positioning for biopharma partners.

75% autonomous resolution rate for DSCSA customer inquiries130+ basis points year-over-year operating margin growth in segmentHalf of segment revenue is third-party logistics; other half is technology services for biopharma

Lisa Gill · J.P. Morgan

After backing out a $51M gain from Q2, oncology margins appear to have improved ~100 bps quarter-over-quarter. What specific drivers (ambient scribing, biosimilars, AI) are improving margins, and what is the forward outlook?

Management confirmed margin improvements are driven by provider platform additions (Florida Cancer, vision platform), specialty and oncology product growth, and early AI/automation capabilities. Expected continued margin accretion from PRISM and Core Ventures acquisitions over time, though noted quarter-to-quarter variability from mix effects.

Specialty and oncology products showing favorable margin impactPRISM and Core Ventures acquisitions expected to be accretive to margins over timeEarly-stage AI/automation capabilities showing margin benefit with expected continued impact

Brian Tancrelot · Jefferies

Any specific puts and takes or nuances for FY2027 guidance? Why did oncology and multi-specialty margins decline ~50 bps sequentially versus ~10 bps decline last year?

Management deferred detailed FY2027 guidance to May but highlighted stable utilization, strong specialty distribution growth, operating efficiency gains (138 bps improvement in OpEx as % of gross profit), and acquisition benefits. Noted segment performing well with 24% organic revenue growth (15% excluding acquisitions) and 15% adjusted operating profit growth.

24% organic revenue growth in oncology/multi-specialty segment15% organic adjusted operating profit growth138 basis points improvement in operating expenses as percentage of gross profitPRISM and Core Ventures expected to be accretive to revenue, profit dollars, and margins

Michael Cherney · Leerink Partners

What is driving the acceleration in North American Pharma growth in Q4 and full year? Any differences in assumptions at top vs. bottom of guidance range?

Management attributed acceleration to: (1) 3% held-for-sale accounting benefit in prior year creating easy comparison; (2) strong specialty growth; (3) health system strength; (4) operational efficiency gains from distribution center and inventory management improvements. Did not specify different drivers for range width.

3% year-over-year impact from held-for-sale accounting in prior year Q3Strong specialty and health system growth continuingOperational efficiency gains in distribution centers and inventory management

Eric Percher · Nephron Research

How is the distributor value proposition holding up against IRA, MFN policies? What areas is management focusing on, and how does it try to influence regulatory outcomes?

Management noted IRA Part D first 10 drugs went live in January (in guidance); maintains constructive manufacturer relationships. Characterized MFN as niche cash-pay population. Assessed GLOBE (Part B) as not material: exempts IRA drugs, applies to 25% of zip codes, ~35% of Medicare oncology business, with rebates direct from manufacturer to Medicare. Strong DC team engaged in policy discussions.

IRA Part D first 10 drugs live in January, included in guidanceMFN assessed as largely niche cash-pay populationGLOBE applies to ~25% of zip codes and ~35% of Medicare oncology businessDirect manufacturer-to-Medicare rebate mechanism in GLOBE

Answers to last quarter's watch list

Q3 North American Pharmaceutical revenue growth vs. the "H2 ~3.5%" implied trajectory. Q3 came in at +9% and 9M YTD at +13% — well above the implied 3.5% and squarely mid-range of the +10–14% FY guide. Per Q&A, a ~3% YoY headwind from prior-year held-for-sale accounting compressed the Q3 print optically, and the FY operating profit guide was raised to +8–12% (from +5–9%). Status: Resolved positively — the demand-side concern didn't materialize, comping framing held up.

Oncology & Multispecialty organic growth disclosure. Management explicitly disclosed organic operating profit growth of +15%. Segment grew +37% YoY total revenue with +57% operating profit. The Q&A quantified 24% organic revenue growth and 15% organic adjusted operating profit growth at the segment level. Status: Resolved positively — organic growth sustained, segment FY guide raised.

Free cash flow conversion against the reaffirmed $4.4–$4.8B guide. 9M YTD free cash flow is $2.17B (Q3 standalone $1.06B) against operating cash flow YTD of $2.7B. Management reaffirmed the $4.4–$4.8B FY range, implying a Q4 of ~$2.2–2.6B — well within prior-year seasonal precedent. Status: Resolved positively — guide reaffirmed with reasonable Q4 math.

Med-Surg IPO disclosures — separation costs, leverage targets, and capital structure language. TSAs across the enterprise went live January 1 — concrete operational milestone confirming the H2 CY2027 IPO timeline. Carve-out financials and capital structure specifics not yet disclosed. Status: Resolved positively — execution proof point delivered; further structural disclosures still pending.

GLP-1 sequential trajectory. GLP-1 revenue $14B in Q3 (+26% YoY, +$3B), up 7% sequentially from Q2's $13.2B. The YoY rate has stabilized in the mid-20s. No biosimilar or payer-policy disruptions cited. Status: Resolved positively — stable, predictable growth component as management framed it.

PTS investment cadence in H2. PTS operating profit growth guide raised to +14–18%, with Q3 adjusted operating margin at 18.47% — running well above the prior peak. Investment step-up didn't compress segment profitability. Status: Resolved positively — raised guide held against the H2 investment cadence.

What to watch into next quarter

Q4 free cash flow conversion against the reaffirmed $4.4–$4.8B FY guide. With 9M YTD free cash flow at $2.17B, Q4 needs to deliver ~$2.2–2.6B — well within prior-year seasonal precedent but still the largest single-quarter conversion of the year. A miss would slow the buyback pace.

FY2027 guidance framework introduced on the May Q4 call. Management deferred detailed FY27 commentary to May. Watch whether the new revenue growth and operating profit growth guides preserve the +13–17% operating profit growth baseline established in FY26, or whether FY27 reverts to a more typical framing without the acquisition tailwind.

North American Pharmaceutical Q4 revenue growth — does YTD stay inside the +10–14% FY guide? 9M YTD is +13%, mid-range. Q4 needs to print roughly in line to keep the FY guide intact. Watch for the prior-year HFS comp roll-off in Q4.

Med-Surg IPO transaction-prep disclosures — carve-out financials and capital structure language. TSAs in place is the operational milestone; the next deliverable is carve-out financial statements and a stated leverage target for the separated business. Absence of either by the May call would soften the H2 CY2027 timeline.

GLP-1 sequential growth — does it hold above $14B in Q4? $12.1B → $13.2B → $14B is a steady $1B step-up cadence. A flat or down Q4 print would be the first material datapoint suggesting GLP-1 has reached its volume plateau and would put consensus FY27 GLP-1 assumptions at risk.

Oncology & Multispecialty organic operating profit growth — does it hold above +15%? The segment is now the primary growth pillar; management leaned into the +15% organic number this quarter. If next quarter's organic OP growth slips below low-teens, the segment-level FY27 narrative weakens despite still-strong headline growth from acquisitions.

Sources

McKesson Q3 FY2026 Earnings Press Release (SEC Exhibit 99.1, period ended December 31, 2025): https://www.sec.gov/Archives/edgar/data/927653/000092765326000015/mck_exhibit991x12312025.htm
McKesson Q3 FY2026 earnings call prepared remarks and Q&A (February 4, 2026)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.